ArticleNeurogastroenterology and motility2025
A Role for High Mobility Group Box 1 (HMGB1) Release in the Pathogenesis of Gastroesophageal Reflux Disease.
Article in Neurogastroenterology and motility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rethinking Long-Term PPI Therapy in GERD: A Narrative Review from a Microbial Ecology Perspective Beyond Acid Suppression.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.ImmunoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMany gastroesophageal reflux disease (GORD) patients have heartburn symptoms despite PPI treatment, potentially via esophageal mucosa exposure to weakly acidic bile salts, leading to oxidative stress. High mobility group box 1 (HMGB1) is a nuclear protein secreted during oxidative stress that binds to receptors including TLR2, TLR4, and RAGE, inducing inflammatory signaling. We describe the release and potential downstream effects of HMGB1 in GORD.
methodsEsophageal biopsies were obtained from healthy controls (HC), functional heartburn (FH), non-erosive reflux disease (NERD), and erosive reflux disease (ERD) patients. Biopsies were analyzed by RNA-sequencing, and the expression of TLR2, TLR4, and RAGE was assessed with immunohistochemistry. NE-1 cells were challenged with pH 5 media and/or 500 μM deoxycholate (DCA), with/without 2-h 5 or 50 μM curcumin pre-treatment. HMGB1 translocation was measured with immunofluorescence and release with ELISA.
resultsHMGB1, alongside 12 additional oxidative stress-associated genes, is over-expressed in NERD and ERD patients compared to HC (adjusted p < 0.05). Weakly acidic bile salt (pH 5 + DCA) stimulated HMGB1 translocation (p < 0.0001) and release from NE-1 cells (p < 0.001), but ameliorated with curcumin pre-treatment. ERD biopsies had increased DAPI+TLR4+ cells (p < 0.05) and TLR4 fluorescence intensity (p < 0.05), compared to HC. RAGE was expressed on CD45+ cells, and the number of RAGE+CD45+ cells was higher in ERD compared to HC (p < 0.05).
conclusionsRelease of HMGB1 from esophageal epithelial cells by weakly acidic bile salts, inhibited by curcumin, and increased expression of TLR4 and RAGE in ERD mucosa suggest this pathway has a role in GORD. Modulating HMGB1 activity may be a strategy for treating recurrent symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.